Cosma, Lidia-Sabina and Weigand, Kilian and Mueller-Schilling, Martina and Kandulski, Arne (2021) Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 30 (2). pp. 247-253. ISSN 1841-8724, 1842-1121
Full text not available from this repository. (Request a copy)Abstract
Background & Aims: Lenvatinib is a multikinase inhibitor approved for systemic first line treatment of hepatocellular cancer (HCC) in patients with compensated liver cirrhosis (LC) and unaltered liver function. We aimed to evaluate the efficiency and tolerability of lenvatinib in patients with HCC in a real world setting, also including patients with advanced LC and impaired liver function. Methods: Retrospectively, 35 patients with HCC BCLC stages B, C and D were screened. After drop-out and exclusion of patients not receiving active treatment for > 2 weeks, 28 patients (27 male; median age 64.7) with advanced HCC and LC were included in the analysis. Results: Fourteen patients (male, median age 62.7) treated had Child-Pugh class B LC, while the other 12 patients had a good liver function Child-Pugh class A (male, median age 68.8). Two patients had advanced Child-Pugh class C LC. The patients received an escalating dosing scheme of lenvatinib up to 12 mg/d. The tolerability of lenvatinib was similar in most of the patients, with no significant difference between the subgroups. Median survival was better in patients with Child-Pugh A LC (p=0.003). More than 60% of the patients with Child-Pugh A were still on treatment at the time of data analysis with a median follow-up of 274 +/- 117.5 days compared with 153 days (95%CI: 88.3 - 217.7) in patients with Child-Pugh B and 30 days in Child-Pugh C. The survival benefit correlated significantly with less impaired liver function (p=0.003). Conclusion: Tolerability and toxicity of lenvatinib are similar in patients with Child-Pugh class A and class B LC, but patients with less impaired liver function have a better survival benefit.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; systemic therapy; lenvatinib; hepatocellular carcinoma; advanced liver cirrhosis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Aug 2022 12:39 |
| Last Modified: | 29 Aug 2022 12:39 |
| URI: | https://pred.uni-regensburg.de/id/eprint/46468 |
Actions (login required)
 |
View Item |
